Drug Search Results
More Filters [+]

HF-0220

Alternative Names: hf-0220, hf0220, hf 0220
Latest Update: 2008-08-21
Latest Update Note: Clinical Trial Update

Product Description

Hunter-Fleming is developing HF-0220 as a treatment for Alzheimer's Disease. (Sourced from: https://clinicaltrials.gov/ct2/show/record/NCT00357357)

Mechanisms of Action: HPGDS Stimulant

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hunter-Fleming
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HF-0220

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Alzheimer Disease|Kidney Diseases|Oxidative Stress|Acute Kidney Injury|Stroke|Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2005-005791-32

P2

Completed

Parkinson's Disease|Stroke|Alzheimer Disease|Kidney Diseases|Oxidative Stress|Acute Kidney Injury

2008-08-11

HF0220/003

P2

Completed

Alzheimer Disease

2008-08-01

Recent News Events

Date

Type

Title